This company has been marked as potentially delisted and may not be actively trading. Vital Therapies (VTL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VTL vs. VIRI, ELYM, CYBN, LITS, WHWK, OSTX, ATNM, AADI, NBRV, and EGRXShould you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include Virios Therapeutics (VIRI), Eliem Therapeutics (ELYM), Cybin (CYBN), Lite Strategy (LITS), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Actinium Pharmaceuticals (ATNM), Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), and Eagle Pharmaceuticals (EGRX). Vital Therapies vs. Its Competitors Virios Therapeutics Eliem Therapeutics Cybin Lite Strategy Whitehawk Therapeutics OS Therapies Actinium Pharmaceuticals Aadi Bioscience Nabriva Therapeutics Eagle Pharmaceuticals Virios Therapeutics (NASDAQ:VIRI) and Vital Therapies (NASDAQ:VTL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk. Which has stronger valuation & earnings, VIRI or VTL? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-19.89Vital TherapiesN/AN/A-$41.47MN/AN/A Is VIRI or VTL more profitable? Virios Therapeutics' return on equity of -130.33% beat Vital Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Vital Therapies N/A -235.33%-182.35% Do insiders & institutionals hold more shares of VIRI or VTL? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Vital Therapies shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 33.9% of Vital Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor VIRI or VTL? In the previous week, Virios Therapeutics' average media sentiment score of 0.00 equaled Vital Therapies'average media sentiment score. Company Overall Sentiment Virios Therapeutics Neutral Vital Therapies Neutral Which has more volatility & risk, VIRI or VTL? Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Vital Therapies has a beta of 3.51, meaning that its share price is 251% more volatile than the S&P 500. SummaryVirios Therapeutics and Vital Therapies tied by winning 3 of the 6 factors compared between the two stocks. Get Vital Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTL vs. The Competition Export to ExcelMetricVital TherapiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.07M$791.90M$6.10B$10.61BDividend YieldN/A4.84%5.67%4.71%P/E RatioN/A1.2986.0526.57Price / SalesN/A29.90611.65131.72Price / CashN/A17.6438.5062.09Price / Book3.107.5412.756.53Net Income-$41.47M-$7.59M$3.31B$276.43M Vital Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTLVital TherapiesN/A$0.90-2.3%N/A-38.7%$38.07MN/A0.0010VIRIVirios TherapeuticsN/A$7.91+43.3%$5.00-36.8%+79.5%$152.33MN/A-29.305Gap DownHigh Trading VolumeELYMEliem TherapeuticsN/A$1.99-6.6%N/A-65.1%$152.03MN/A-3.759CYBNCybinN/A$5.89-1.7%$85.00+1,343.1%N/A$150.88MN/A-1.3450LITSLite StrategyN/A$2.42-4.7%N/AN/A$90.56M$65.30M0.00100News CoverageAnalyst ForecastWHWKWhitehawk Therapeutics0.9948 of 5 stars$1.90-1.0%N/AN/A$90.49M$25.98M-31.6721News CoveragePositive NewsAnalyst UpgradeOSTXOS TherapiesN/A$1.96-2.5%$18.00+818.4%N/A$62.02MN/A-2.48N/AATNMActinium Pharmaceuticals1.8628 of 5 stars$1.60-1.2%$4.50+181.3%-8.6%$49.91MN/A-1.1530AADIAadi BioscienceN/A$1.92-1.0%N/A+9.0%$47.42M$25.07M-0.8440NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070EGRXEagle Pharmaceuticals1.3542 of 5 stars$2.70-4.4%N/A+166.7%$35.07M$257.55M0.00100 Related Companies and Tools Related Companies VIRI Competitors ELYM Competitors CYBN Competitors LITS Competitors WHWK Competitors OSTX Competitors ATNM Competitors AADI Competitors NBRV Competitors EGRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTL) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vital Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vital Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
